IBB0979 + topotecan

IBB0979 + topotecan is a **combination therapy** being investigated for relapsed small cell lung cancer (SCLC). This formulation consists of IBB0979, a novel B7H3-IL10 immunocytokine, combined with topotecan, a topoisomerase I inhibitor chemotherapeutic agent. - **IBB0979** is the first-in-class immunocytokine targeting B7H3 (CD276), fused to interleukin-10 (IL-10), aiming to enhance anti-tumor immune response by binding to B7H3 expressed on tumor cells and delivering IL-10 to the tumor microenvironment, thus promoting immunomodulation and direct antitumor effects[4][6][7]. - **Topotecan** is a well-established chemotherapeutic that inhibits DNA topoisomerase I, leading to DNA damage and cell death, primarily in rapidly dividing tumor cells. The combination is under clinical study to evaluate whether the immunomodulatory action of IBB0979 enhances or synergizes with the cytotoxic effects of topotecan in patients with SCLC that has relapsed after previous treatment. The primary indication under investigation is relapsed small cell lung cancer. The therapy is in Phase II/III clinical trials[1][5][7][9]. Both IBB0979 and topotecan are administered intravenously.